Cargando…
Synthetic ACTH in High Risk Patients with Idiopathic Membranous Nephropathy: A Prospective, Open Label Cohort Study
New therapeutic agents are warranted in idiopathic membranous nephropathy. Synthetic ACTH may be advantageous with reported remission rates up to 85% and few side effects. We conducted a prospective open label cohort study from 2008 till 2010 (NCT00694863). We prospectively selected patients with id...
Autores principales: | van de Logt, Anne-Els, Beerenhout, Charles H., Brink, Hans S., van de Kerkhof, Jos J., Wetzels, Jack F., Hofstra, Julia M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642982/ https://www.ncbi.nlm.nih.gov/pubmed/26562836 http://dx.doi.org/10.1371/journal.pone.0142033 |
Ejemplares similares
-
COVID-19 Vaccination in Patients With Membranous Nephropathy
por: Visch, Ruben, et al.
Publicado: (2022) -
Antibody-Guided Therapy in Phospholipase A2 Receptor-Associated Membranous Nephropathy
por: Vink, Coralien H., et al.
Publicado: (2022) -
Anti-PLA2R1 Antibodies as Prognostic Biomarker in Membranous Nephropathy
por: Logt, Anne-Els van de, et al.
Publicado: (2021) -
TRPC6 Single Nucleotide Polymorphisms and Progression of Idiopathic Membranous Nephropathy
por: Hofstra, Julia M., et al.
Publicado: (2014) -
A European multicentre and open-label controlled randomized trial to evaluate the efficacy of Sequential treatment with TAcrolimus–Rituximab versus steroids plus cyclophosphamide in patients with primary MEmbranous Nephropathy: the STARMEN study
por: Rojas-Rivera, Jorge, et al.
Publicado: (2015)